Authors: Wirtz, PW Roep, BO Schreuder, GMT van Doorn, PA van Engelen, BGM Kuks, JB Twijnstra, A de Visser, M Visser, LH Wokke, JH Wintzen, AR Verschuuren, JJ

Citation: Pw. Wirtz et al., HLA class I and II in Lambert-Eaton myasthenic syndrome without associatedtumor, HUMAN IMMUN, 62(8), 2001, pp. 809-813

Authors: De Letter, MACJ van Doorn, PA Savelkoul, HFJ Laman, JD Schmitz, PIM Op de Coul, AAW Visser, LH Kros, JM Teepen, JLJM van der Meche, FGA

Citation: Macj. De Letter et al., Critical illness polyneuropathy and myopathy (CIPNM): evidence for local immune activation by cytokine-expression in the muscle tissue, J NEUROIMM, 106(1-2), 2000, pp. 206-213

Authors: De Letter, MACJ Visser, LH De Letter, MACJ Ang, W Van der Meche, FGA Ang, W Savelkoul, HFJ

Citation: Macj. De Letter et al., Distinctions between critical illness polyneuropathy and axonal Guillain-Barre syndrome, J NE NE PSY, 68(3), 2000, pp. 397-398

Authors: Megens-de Letter, MACJ Visser, LH van Doorn, PA Savelkoul, HFJ

Citation: Macj. Megens-de Letter et al., Cytokines in the muscle tissue of idiopathic inflammatory myopathies: implications for immunopathogenesis and therapy, EUR CYTOKIN, 10(4), 1999, pp. 471-477

Authors: Visser, LH Schmitz, PIM Meulstee, J van Doorn, PA van der Meche, FGA

Citation: Lh. Visser et al., Prognostic factors of Guillain-Barre syndrome after intravenous immunoglobulin or plasma exchange, NEUROLOGY, 53(3), 1999, pp. 598-604